CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, CareDx (CDNA) reported revenue of $100.06 million, up 20.7% over the same period last year. EPS came in at $0.28, compared to $0.14 in the year-ago quarter.The reported revenue represents a surprise of +5.07% over the Zacks Consensus Estimate of $95.23 million. With the consensus EPS estimate being $0.13, the EPS surprise was +115.38%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how CareDx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Patient and digital solutions: $15.41 million versus the three-analyst average estimate of $13.63 million. The reported number represents a year-over-year change of +29.9%.Revenue- Testing services: $72.17 million versus the three-analyst average estimate of $69.48 million. The reported number represents a year-over-year change of +18.7%.Revenue- Product: $12.48 million compared to the $12.13 million average estimate based on three analysts. The reported number represents a change of +22.2% year over year.View all Key Company Metrics for CareDx here>>>Shares of CareDx have returned -1.3% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CareDx, Inc. (CDNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks